PH30430A - Method for lowering serum cholesterol - Google Patents

Method for lowering serum cholesterol

Info

Publication number
PH30430A
PH30430A PH47481A PH47481A PH30430A PH 30430 A PH30430 A PH 30430A PH 47481 A PH47481 A PH 47481A PH 47481 A PH47481 A PH 47481A PH 30430 A PH30430 A PH 30430A
Authority
PH
Philippines
Prior art keywords
alkanoyloxy
substituted
unsubstituted
serum cholesterol
lowering serum
Prior art date
Application number
PH47481A
Other languages
English (en)
Inventor
Larry John Cullinan Geor Black
Henry Uhlman Bryant
Raymond Francis Kauffman
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PH30430A publication Critical patent/PH30430A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Bipolar Transistors (AREA)
  • Semiconductor Lasers (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PH47481A 1992-12-22 1993-12-17 Method for lowering serum cholesterol PH30430A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US99522292A 1992-12-22 1992-12-22

Publications (1)

Publication Number Publication Date
PH30430A true PH30430A (en) 1997-05-09

Family

ID=25541537

Family Applications (1)

Application Number Title Priority Date Filing Date
PH47481A PH30430A (en) 1992-12-22 1993-12-17 Method for lowering serum cholesterol

Country Status (28)

Country Link
US (1) US5464845A (es)
EP (2) EP1238667A3 (es)
JP (1) JP3197129B2 (es)
KR (1) KR100278946B1 (es)
CN (1) CN1043608C (es)
AT (1) ATE233559T1 (es)
AU (1) AU669235B2 (es)
BG (1) BG61524B1 (es)
BR (1) BR9305182A (es)
CA (1) CA2112017C (es)
CZ (1) CZ283863B6 (es)
DE (1) DE69332735T2 (es)
DK (1) DK0605193T3 (es)
ES (1) ES2193142T3 (es)
HU (1) HU223342B1 (es)
IL (1) IL108042A (es)
MY (1) MY109345A (es)
NO (1) NO304924B1 (es)
NZ (1) NZ250486A (es)
PH (1) PH30430A (es)
PL (1) PL177349B1 (es)
RO (1) RO113806B1 (es)
RU (1) RU2123335C1 (es)
SG (1) SG52696A1 (es)
SK (1) SK279271B6 (es)
TW (1) TW383306B (es)
YU (1) YU48918B (es)
ZA (1) ZA939427B (es)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE39049E1 (en) 1992-07-28 2006-03-28 Eli Lilly And Company Methods for inhibiting bone loss
USRE38968E1 (en) 1992-07-28 2006-02-07 Eli Lilly And Company Methods for inhibiting bone loss using 6-hydroxy-2-(4-hydroxyphenyl)-benzo[b]thien-3-yl-4-[2-(piperidin-1-yl) ethoxyphenylimethanone hydrochloride
TW366342B (en) * 1992-07-28 1999-08-11 Lilly Co Eli The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
US5482949A (en) * 1993-03-19 1996-01-09 Eli Lilly And Company Sulfonate derivatives of 3-aroylbenzo[b]thiophenes
WO1996040098A2 (en) * 1995-06-07 1996-12-19 Neorx Corporation Prevention and treatment of cardiovascular pathologies with tamoxifen analogues
US5482950A (en) * 1993-10-15 1996-01-09 Eli Lilly And Company Methods for lowering serum cholesterol
US6489355B2 (en) * 1993-12-01 2002-12-03 Eli Lilly And Company Methods of inhibiting the effects of amyloidogenic proteins
CZ306394A3 (en) * 1993-12-14 1995-08-16 Lilly Co Eli Aqueous solution of inclusion complex of benzothiophene derivative with water-soluble cyclodextrins, process of its preparation and a pharmaceutical composition containing thereof
US6417198B1 (en) 1993-12-21 2002-07-09 Eli Lilly And Company Methods of inhibiting CNS problems in post-menopausal women
RU2127592C1 (ru) * 1993-12-21 1999-03-20 Эли Лилли Энд Компани Средство для ингибирования окисления липидов низкой плотности и подавления атеросклероза
US5441966A (en) * 1993-12-21 1995-08-15 Eli Lilly And Company Methods of inhibiting Turner's syndrome
US5478847A (en) * 1994-03-02 1995-12-26 Eli Lilly And Company Methods of use for inhibiting bone loss and lowering serum cholesterol
US5629425A (en) * 1994-09-19 1997-05-13 Eli Lilly And Company Haloalkyl hemisolvates of 6-hydroxy-2-(4-hydroxyphenyl)-3-[4-piperidinoethoxy)-benzoyl]benzo[b]thiophene
CO4410191A1 (es) 1994-09-19 1997-01-09 Lilly Co Eli SINTESIS DE 3-[4-(2-AMINOETOXI)BENZOIL]-2-ARIL-6- HIDROXIBENZO [b] TIOFENOS
US6562862B1 (en) * 1994-10-20 2003-05-13 Eli Lilly And Company Methods of inhibiting physiological conditions associated with an excess of neuropeptide Y
WO1996012489A1 (en) * 1994-10-20 1996-05-02 Eli Lilly And Company Bicyclic neuropeptide y receptor antagonists
US5552412A (en) 1995-01-09 1996-09-03 Pfizer Inc 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis
US5484808A (en) * 1995-02-09 1996-01-16 Eli Lilly And Company Methods of inhibiting cell-cell adhesion
WO1996032937A1 (en) * 1995-04-21 1996-10-24 Eli Lilly And Company Benzothiophenes with novel basic side chains
US5731328A (en) * 1995-10-10 1998-03-24 Eli Lilly And Company Methods of inhibiting plasminogen activator inhibitor 1
US5726168A (en) * 1995-10-12 1998-03-10 Eli Lilly And Company Lipophilic benzothiophenes
IL120266A (en) * 1996-02-28 2005-05-17 Pfizer Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions
TW442286B (en) * 1996-02-28 2001-06-23 Pfizer New therapeutic uses of estrogen agonists
HN1996000101A (es) 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis
EP0801066A1 (en) * 1996-03-12 1997-10-15 Eli Lilly And Company Heterocyclic substituted benzothiophenes and pharmaceutical compositions
AU5258696A (en) * 1996-03-19 1997-10-10 Eli Lilly And Company Synthesis of 3-{4-(2-aminoethoxy)-benzoyl}-2-aryl-6-hydroxy-benzo{b}thiop henes
US6458811B1 (en) 1996-03-26 2002-10-01 Eli Lilly And Company Benzothiophenes formulations containing same and methods
US5811437A (en) * 1996-05-21 1998-09-22 Eli Lilly And Company Methods of increasing nitric oxide synthesis
US5747509A (en) * 1996-06-03 1998-05-05 Schering Aktiengesellschaft Method for lowering plasma levels of lipoprotein(a)
CA2206752A1 (en) * 1996-07-02 1998-01-02 George Joseph Cullinan Benzothiophene compounds, intermediates, processes, and methods of use
US5980938A (en) * 1996-07-15 1999-11-09 Eli Lilly And Company Effect of compounds that suppress induction of plasminogen activator inhibitor 1 (PAI-1)
CA2214072C (en) * 1996-08-29 2006-11-14 Eli Lilly And Company Benzo [b] thiophene compounds, intermediates, processes, compositions, and methods
US5773432A (en) * 1996-10-30 1998-06-30 Schering Aktiengesellschaft Method for lowering plasma levels of lipoprotein(a)
UA59384C2 (uk) 1996-12-20 2003-09-15 Пфайзер, Інк. Похідні сульфонамідів та амідів як агоністи простагландину, фармацевтична композиція та способи лікування на їх основі
CN1252717A (zh) * 1997-04-30 2000-05-10 伊莱利利公司 制备苯并[b]噻吩的中间体和方法
CA2231013A1 (en) * 1997-04-30 1998-10-30 Eli Lilly And Company Process for preparing benzoic acid derivative intermediates and benzothiophene pharmaceuticals
JP2001522372A (ja) * 1997-04-30 2001-11-13 イーライ・リリー・アンド・カンパニー ベンゾチオフェンの製造方法
CA2287922A1 (en) * 1997-04-30 1998-11-05 Eli Lilly And Company Intermediates and processes for preparing benzo[b]thiophenes
CA2236254A1 (en) * 1997-04-30 1998-10-30 David Warren Hoard Process for preparing benzo¬b|thiophenes
CN1254280A (zh) * 1997-04-30 2000-05-24 伊莱利利公司 用于制备取代的苯并[b]噻吩的区域选择性烷基化方法
US6124314A (en) * 1997-10-10 2000-09-26 Pfizer Inc. Osteoporosis compounds
US6096781A (en) * 1997-11-14 2000-08-01 Eli Lilly And Company 2-arylbenzo[B]thiophenes useful for the treatment of estrogen deprivation syndrome
US6465445B1 (en) 1998-06-11 2002-10-15 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
US7005428B1 (en) 1998-06-11 2006-02-28 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
US6353003B1 (en) 1998-06-17 2002-03-05 Eli Lilly And Company Method for reducing levels of homocysteine and C-reactive protein
US6258826B1 (en) 1998-10-13 2001-07-10 Eli Lilly And Company Pharmaceutical formulations and applications thereof for the treatment of estrogen deprivation syndrome
SK287795B6 (sk) * 1999-02-06 2011-10-04 Astrazeneca Ab Kombinácia vzájomne nereagujúcich liečiv obsahujúca inhibítor HMG-CoA reduktázy a inhibítor, induktor alebo substrát P450 izoenzýmu 3A4
AP2002002555A0 (en) 1999-12-22 2002-06-30 Pfizer Prod Inc EP4 Receptor selective agonists in the treatment of osteoporosis.
ES2274854T3 (es) * 2000-05-08 2007-06-01 Pfizer Products Inc. Resolucion enzimatica de moduladores selectivos del receptor de estrogeno.
US20030216358A1 (en) * 2001-07-05 2003-11-20 Muchmore Douglas Boyer Method for enhancing bone mineral density gain
RU2355397C2 (ru) * 2002-06-13 2009-05-20 Уайт Режимы лечения базедоксифеном
US20060106010A1 (en) * 2003-05-27 2006-05-18 Black Larry J Methods for inhibiting bone loss
MXPA06006810A (es) * 2003-12-17 2006-08-23 Pfizer Prod Inc Tratamiento de afecciones que se presentan con un nivel bajo de masa osea por terapia de combinacion continua con agonistas selectivos del receptor de prostaglandina ep4 y un estrogeno.
US8257007B2 (en) 2007-07-27 2012-09-04 Container Stuffers, Llc Cargo loader
CN101669557B (zh) * 2009-08-20 2012-07-25 杭州六易科技有限公司 一种清热解毒凉茶的制作方法
US20170298081A1 (en) * 2014-08-08 2017-10-19 Kasuma Partners Inc. Condensed heterocyclic compound

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4133814A (en) * 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
ES8602577A1 (es) * 1983-06-24 1985-12-01 Yamanouchi Pharma Co Ltd Un procedimiento para la preparacion de un compuesto fenoxi
EP0166025A3 (en) * 1984-06-27 1986-08-20 American Cyanamid Company Non-antibiotic animal feed additive compositions
US4729999A (en) * 1984-10-12 1988-03-08 Bcm Technologies Antiestrogen therapy for symptoms of estrogen deficiency
AT391316B (de) * 1988-09-15 1990-09-25 Ebewe Arzneimittel Neue thienyloxy-alkylamin-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
TW366342B (en) * 1992-07-28 1999-08-11 Lilly Co Eli The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
US5441964A (en) * 1993-10-15 1995-08-15 Eli Lilly And Company Methods for inhibiting bone loss using substituted benzothiophene

Also Published As

Publication number Publication date
PL177349B1 (pl) 1999-10-29
AU669235B2 (en) 1996-05-30
NO934740D0 (no) 1993-12-21
DE69332735T2 (de) 2003-10-23
HUT69686A (en) 1995-09-28
EP0605193A1 (en) 1994-07-06
YU79893A (sh) 1997-05-28
MY109345A (en) 1997-01-31
KR940013501A (ko) 1994-07-15
ATE233559T1 (de) 2003-03-15
YU48918B (sh) 2002-11-15
US5464845A (en) 1995-11-07
HU223342B1 (hu) 2004-06-28
NO934740L (no) 1994-06-23
EP1238667A3 (en) 2003-12-10
SK142193A3 (en) 1995-01-12
CN1043608C (zh) 1999-06-16
CZ279093A3 (en) 1994-07-13
JP3197129B2 (ja) 2001-08-13
SG52696A1 (en) 1998-09-28
BR9305182A (pt) 1994-08-16
JPH06234632A (ja) 1994-08-23
CA2112017A1 (en) 1994-06-23
DK0605193T3 (da) 2003-03-31
RU2123335C1 (ru) 1998-12-20
KR100278946B1 (ko) 2001-01-15
TW383306B (en) 2000-03-01
SK279271B6 (sk) 1998-08-05
IL108042A (en) 1998-01-04
IL108042A0 (en) 1994-04-12
RO113806B1 (ro) 1998-11-30
NZ250486A (en) 1997-06-24
CZ283863B6 (cs) 1998-06-17
DE69332735D1 (de) 2003-04-10
ES2193142T3 (es) 2003-11-01
PL301579A1 (en) 1994-06-27
NO304924B1 (no) 1999-03-08
EP1238667A2 (en) 2002-09-11
BG61524B1 (bg) 1997-11-28
HU9303676D0 (en) 1994-04-28
EP0605193B1 (en) 2003-03-05
CN1094042A (zh) 1994-10-26
BG98317A (en) 1995-02-28
AU5257893A (en) 1994-07-07
CA2112017C (en) 2005-06-14
ZA939427B (en) 1995-06-15

Similar Documents

Publication Publication Date Title
AU669235B2 (en) Improvements in or relating to benzothiophenes
PL309874A1 (en) Novel derivatives of pyrrolocarbasol, method of obtaining them and pharmaceutical composition containing such derivatives
AU8156394A (en) Methods for inhibiting LDL oxidation and atheroclerosis
EP0436734A4 (en) New aminopiperazine derivatives
HU9601590D0 (en) Method of lowering serum cholesterol levels with 2,6-dialkyl-4-silyl-phenols
AU543677B2 (en) 5,10-dihyro-11h-dibenzo(b,e)(1,4)diazepine-11-ones
KR960009425B1 (en) Novel diphenylthiazole derivative
AU625238B2 (en) Anti-psychotic piperidylbenzimidazole compounds
PL299541A1 (en) Novel derivatives of n-[(4-aminocarbonylopyrimidino-2)-aminoalkyl]-2-aminopyrimidine carrbonamide-4, method of obtaining them, drug and pharmaceutical preparation
NO20000750D0 (no) Fremgangsmåte for å redusere blodplatetall
HUT64345A (en) Methods for producing amino-alkyl-pyrrolidinyl-thio-carbapeneme derivatives and pharmaceutical preparatives containing them as active agent
PH18574A (en) Substituted 11-oxo-11h-pyrido 2,i-h -quinazoline derivatives,pharmaceutical compositions containing them and method of use thereof
AU6703090A (en) New substituted benzothiazolinones, process for preparing these and pharmaceutical compositions containing them
JPS6426559A (en) Novel phthalide derivative
BG95629A (en) Derivatives of 10, 11, 12, 13 - tetrahytdrodesmicozine, method for preparing them, and their use as pharmaceutical preparations
JPS5430166A (en) 2-aminomethyl-5-phenyloxazoles and their pharmaceutically acceptable acid salts